Ventyx Biosciences, Inc. (NASDAQ:VTYX) Stock Position Raised by Cubist Systematic Strategies LLC

Cubist Systematic Strategies LLC lifted its position in Ventyx Biosciences, Inc. (NASDAQ:VTYX) by 165.8% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 149,500 shares of the company’s stock after buying an additional 93,247 shares during the quarter. Cubist Systematic Strategies LLC owned about 0.21% of Ventyx Biosciences worth $345,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Deerfield Management Company L.P. Series C grew its position in Ventyx Biosciences by 64.6% in the second quarter. Deerfield Management Company L.P. Series C now owns 5,829,570 shares of the company’s stock worth $13,466,000 after acquiring an additional 2,287,570 shares in the last quarter. Farallon Capital Management LLC acquired a new position in Ventyx Biosciences during the first quarter worth $17,435,000. Redmile Group LLC raised its holdings in Ventyx Biosciences by 944.4% during the first quarter. Redmile Group LLC now owns 2,164,126 shares of the company’s stock valued at $11,903,000 after buying an additional 1,956,923 shares in the last quarter. Opaleye Management Inc. lifted its position in shares of Ventyx Biosciences by 12.7% in the first quarter. Opaleye Management Inc. now owns 1,285,000 shares of the company’s stock worth $7,068,000 after buying an additional 145,000 shares during the last quarter. Finally, First Light Asset Management LLC bought a new stake in shares of Ventyx Biosciences during the 1st quarter worth about $3,437,000. Institutional investors and hedge funds own 97.88% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the company. HC Wainwright reiterated a “neutral” rating and set a $6.00 price target on shares of Ventyx Biosciences in a report on Monday, September 23rd. Wells Fargo & Company lowered their price target on Ventyx Biosciences from $16.00 to $11.00 and set an “overweight” rating on the stock in a research report on Monday, August 12th. Finally, Canaccord Genuity Group cut their price objective on Ventyx Biosciences from $15.00 to $14.00 and set a “buy” rating for the company in a research report on Monday, August 12th. Four investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, Ventyx Biosciences presently has a consensus rating of “Moderate Buy” and a consensus price target of $8.29.

Ventyx Biosciences Stock Up 4.4 %

VTYX stock opened at $2.14 on Monday. Ventyx Biosciences, Inc. has a twelve month low of $1.79 and a twelve month high of $20.39. The company has a market cap of $151.23 million, a PE ratio of -0.77 and a beta of 0.36. The business’s 50-day simple moving average is $2.15 and its 200 day simple moving average is $3.19.

Ventyx Biosciences (NASDAQ:VTYX) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.45) earnings per share for the quarter, topping the consensus estimate of ($0.57) by $0.12. On average, equities research analysts anticipate that Ventyx Biosciences, Inc. will post -2.14 EPS for the current year.

Ventyx Biosciences Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.